Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
CYRX 
Cryoport Inc (CYRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: CYRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $13.22
1 Year Target Price $13.22
| 4 | Strong Buy |
| 2 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -41.42% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 525.72M USD | Price to earnings Ratio - | 1Y Target Price 13.22 |
Price to earnings Ratio - | 1Y Target Price 13.22 | ||
Volume (30-day avg) 10 | Beta 1.54 | 52 Weeks Range 4.58 - 11.44 | Updated Date 01/8/2026 |
52 Weeks Range 4.58 - 11.44 | Updated Date 01/8/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 29.23% | Operating Margin (TTM) -22.01% |
Management Effectiveness
Return on Assets (TTM) -4.39% | Return on Equity (TTM) -11.3% |
Valuation
Trailing PE - | Forward PE 58.14 | Enterprise Value 375544492 | Price to Sales(TTM) 2.16 |
Enterprise Value 375544492 | Price to Sales(TTM) 2.16 | ||
Enterprise Value to Revenue 1.54 | Enterprise Value to EBITDA -13 | Shares Outstanding 50068904 | Shares Floating 40815670 |
Shares Outstanding 50068904 | Shares Floating 40815670 | ||
Percent Insiders 3.85 | Percent Institutions 102.12 |
Upturn AI SWOT
Cryoport Inc
Company Overview
History and Background
Cryoport Inc. was founded in 2002 and has evolved into a global leader in temperature-controlled logistics and cryogenic supply chain solutions. The company has experienced significant growth, driven by its focus on the life sciences sector, including biopharmaceutical, reproductive medicine, and regenerative medicine industries. Key milestones include strategic acquisitions and the expansion of its global network of service centers.
Core Business Areas
- Cryoport Expressu00ae Logistics: Provides temperature-controlled logistics solutions for the life sciences industry, specializing in the transport of vital biological materials such as cell and gene therapies, stem cells, and reproductive tissues. This includes advanced packaging, real-time temperature monitoring, and specialized shipping services.
- Cryoport Life Sciences: Offers a suite of services designed to support the biopharmaceutical and life sciences industries throughout the drug development lifecycle, from clinical trials to commercialization. This encompasses sample management, biobanking, and specialized cold chain solutions.
- Cryoport Data Services: Provides cloud-based solutions for managing and tracking biological samples and logistics data, enhancing transparency and compliance within the supply chain.
Leadership and Structure
Cryoport Inc. is led by a seasoned management team with expertise in logistics, life sciences, and technology. The company operates with a divisional structure, aligning its services with specific industry needs, and maintains a global presence with strategically located service centers.
Top Products and Market Share
Key Offerings
- Description: This is Cryoport's flagship service, offering end-to-end temperature-controlled logistics for high-value biological materials. It leverages proprietary packaging, advanced data loggers, and a global network. Market share data for specific products is not publicly disclosed, but Cryoport is a recognized leader in the specialized cold chain logistics for cell and gene therapies. Key competitors include World Courier (a division of AmerisourceBergen), PCI Pharma Services, and various regional logistics providers.
- Product Name 1: Cryoport Expressu00ae Logistics
- Description: A comprehensive platform that integrates logistics, sample management, and data services for the biopharmaceutical industry. This offering caters to the complex needs of drug development and clinical trials. Competitors are often broad-based logistics companies with life science divisions or specialized sample management providers.
- Product Name 2: Cryoport Life Sciences Solutions
Market Dynamics
Industry Overview
The temperature-controlled logistics market, particularly for biologics and specialized pharmaceuticals, is experiencing robust growth driven by advancements in cell and gene therapies, personalized medicine, and the increasing complexity of global supply chains. The demand for reliable, temperature-sensitive cold chain solutions is paramount.
Positioning
Cryoport is well-positioned as a specialized provider within the critical life sciences cold chain segment. Its competitive advantages lie in its deep industry expertise, proprietary technology for temperature monitoring and control, global infrastructure, and a strong focus on compliance and quality.
Total Addressable Market (TAM)
The global biopharmaceutical logistics market, encompassing cold chain, is estimated to be in the tens of billions of dollars and is projected to continue growing at a significant CAGR. Cryoport is targeting a substantial portion of this TAM by focusing on high-growth sub-segments like cell and gene therapies, where specialized logistics are critical and less commoditized. Cryoport's positioning is strong within its niche, but the overall market includes many broader logistics players.
Upturn SWOT Analysis
Strengths
- Specialized expertise in the life sciences cold chain.
- Proprietary technology for temperature control and monitoring.
- Global network of service centers.
- Strong customer relationships in the biopharmaceutical sector.
- Focus on high-growth segments like cell and gene therapies.
Weaknesses
- Reliance on a few key customer segments.
- Potential for high operational costs associated with specialized logistics.
- Need for continuous investment in technology and infrastructure.
- Competition from larger, established logistics providers with broader capabilities.
Opportunities
- Continued growth in the cell and gene therapy market.
- Expansion into new geographic regions.
- Development of new service offerings and technologies.
- Strategic partnerships and acquisitions to enhance capabilities.
- Increasing demand for real-time data and supply chain transparency.
Threats
- Regulatory changes impacting biopharmaceutical logistics.
- Intensifying competition from established and emerging players.
- Economic downturns affecting biopharmaceutical R&D and manufacturing.
- Disruptions in global supply chains (e.g., geopolitical events, pandemics).
- Technological advancements by competitors that could render current solutions less competitive.
Competitors and Market Share
Key Competitors
- World Courier (AmerisourceBergen)
- PCI Pharma Services
- Thermo Fisher Scientific (partially)
- Kuehne+Nagel (life sciences division)
Competitive Landscape
Cryoport's advantages lie in its specialized focus and advanced technology for the niche biopharmaceutical cold chain. However, it faces competition from larger, diversified logistics providers that can offer broader services, and from specialized players with established client bases. Cryoport's challenge is to maintain its leadership in its niche while scaling its operations to meet growing demand.
Major Acquisitions
Cryoport acquired the assets of Bio-Genetics, Inc.
- Year: 2021
- Acquisition Price (USD millions):
- Strategic Rationale: This acquisition was aimed at enhancing Cryoport's capabilities in laboratory services and specimen management, further integrating its service offerings for the life sciences sector.
Cryoport acquired a majority stake in Cryogenic Systems Inc.
- Year: 2019
- Acquisition Price (USD millions):
- Strategic Rationale: This acquisition bolstered Cryoport's expertise and offerings in cryogenic equipment and services, complementing its core logistics business.
Growth Trajectory and Initiatives
Historical Growth: Cryoport has demonstrated consistent historical revenue growth, largely fueled by the expansion of the biopharmaceutical industry, particularly in the cell and gene therapy space. The company has also strategically expanded its service offerings and geographic reach.
Future Projections: Analyst projections for Cryoport generally indicate continued strong revenue growth, supported by increasing demand for its specialized logistics solutions and its strategic positioning in high-growth life science segments. The company is expected to benefit from the ongoing innovation in regenerative medicine and advanced therapies.
Recent Initiatives: Recent strategic initiatives likely include continued investment in its global infrastructure, expansion of its service portfolio to meet evolving industry needs, and potential strategic partnerships or acquisitions to further solidify its market position.
Summary
Cryoport Inc. is a strong niche player in the rapidly growing temperature-controlled logistics market for life sciences. Its specialized expertise and proprietary technology are key strengths, positioning it well for continued growth in the cell and gene therapy sector. However, the company needs to continuously innovate and manage its operational costs to stay ahead of competitors and navigate potential market disruptions.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company investor relations website
- Industry research reports
- Financial news outlets
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cryoport Inc
Exchange NASDAQ | Headquaters Brentwood, TN, United States | ||
IPO Launch date 2005-03-15 | Chairman, President & CEO Mr. Jerrell W. Shelton | ||
Sector Industrials | Industry Integrated Freight & Logistics | Full time employees 1090 | Website https://www.cryoportinc.com |
Full time employees 1090 | Website https://www.cryoportinc.com | ||
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and cryogenic biostorage within the life science industry. Its Life Sciences Products segment offers cryogenic freezers, cryogenic dewars, and accessories within the life science industry through direct sales or a distribution network. The company's products include Cryoport Express Shippers; Cryoport ELITE Shippers; Cryoport Express Cryogenic HV3 Shipping System; Smartpak II Condition Monitoring System and Tec4Med; and Cryoport accessories. It also provides Cryoport BioStorage/Bioservices, such as CRYOGENE, a biostorage solution for the provision of pre-clinical temperature-controlled biological materials management services; and Cryoport Systems Bioservices, including controlled temperature storage, kitting, labelling, fulfillment, sample management, drug return, and Qualified Person drug product release. In addition, the company offers IntegriCell services that comprise apheresis/leukapheresis collection, cryoshuttle transportation, cryo-process optimization, and cryopreservation services; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; CRYOPDP, a temperature-controlled logistics solution; MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; and Vario cryogenic system, a cryogenic freezer system. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. The company was founded in 1999 and is based in Brentwood, Tennessee.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.